Revisiting beta-2 microglobulin as a prognostic marker in diffuse large B-cell lymphoma.
Jelena JelicicKaren Juul-JensenZoran BukumiricMikkel Runason SimonsenMichael Roost ClausenAhmed Ludvigsen Al-MashhadiRobert Schou PedersenChristian Bjørn PoulsenAnne Ortved GangPeter de Nully BrownTarec Christoffer El-GalalyThomas Stauffer LarsenPublished in: Cancer medicine (2024)
International Prognostic Indices, except for NCCN-IPI, fail to accurately discriminate risk groups in the rituximab era. β2M, a readily available marker, could improve the discriminatory performance of NCCN-IPI and should be re-evaluated in the development setting of future models for DLBCL.